Recently, Jiangsu Hengrui Medicine independently developed a class 1 new drug, Retagliptin Phosphate (trade name: Ruizetang), which was approved by the National Medical Products Administration for marketing. This is the first independently developed Dipeptidyl peptidase-4 inhibitor (DPP-4i) drug in China. It is used to improve the blood sugar control of adult type 2 diabetes patients, and will provide new options for personalized treatment of such patients. So far, Jiangsu Hengrui Medicine has increased to 2 self developed innovative drugs in the field of metabolic diseases. At the same time as repagliptin, Jiangsu Hengrui Medicine's Class 1 innovative antifungal drug Oteconazole was approved for the treatment of severe vulvovaginal candidiasis (VVC, also known as mycotic Vaginitis). The listing of Otoconazole will provide new treatment options for VVC patients. At the same time, it is the first Class 1 innovative drug product launched in the field of anti infection treatment of Jiangsu Hengrui Medicine. The company's product pipeline continues to expand. The first independently developed DPP-4i drug in China helps type 2 diabetes patients to control blood sugar. Treatment of diabetes should comprehensively consider multiple factors such as blood sugar control, complication prevention, drug safety and individual differences of patients. Although the existing treatment scheme has achieved some results, it still faces many challenges, especially the hypoglycemia event during the treatment of type 2 diabetes, which increases the difficulty of treatment and affects the survival of patients. The characteristics of individual differences of diabetes patients need to match the individualized treatment plan. The approval and listing of repagliptin is based on two multicenter, randomized, double-blind, placebo parallel controlled phase III studies (repagliptin phase IIIa/repagliptin phase IIIc), with the relative baseline change of Glycated hemoglobin (HbA1c) as the main endpoint. Phase Ⅲ a clinical study of repagliptin showed that repagliptin 100mg QD alone could reduce HbA1c of type 2 diabetes patients by 1.13%, and reduce postprandial blood glucose by 2.69mmol/L. Phase III c clinical study of repagliptin showed that repagliptin 50mg Bid combined with Metformin could further reduce the HbA1c of type 2 diabetes patients by 1.18%, and reduce the postprandial blood glucose by 2.71mmol/L, providing stable blood glucose management for diabetes patients. It is worth mentioning that the medication regimen of repagliptin is flexible, which can be taken either once a day or twice a day, which is beneficial for improving patient compliance. In addition, the unique hypoglycemic mechanism of DPP-4 inhibitor can be combined with other hypoglycemic drugs, which will promote personalized combined treatment of diabetes patients. Hengrui is the first listed Class 1 innovative drug in the field of anti infection. New fungal inhibitor provides new clinical treatment options. Vulvovaginal candidiasis (VVC) is a common and frequently occurring disease among women of childbearing age, also known as mycotic Vaginitis and vulvovaginal candidiasis. The recurrent and difficult to cure characteristics of VVC have already affected the quality of life of patients; However, the efficacy of existing standard therapeutic drugs for VVC is limited, and the risks of drug resistance and safety cannot be ignored. The clinical treatment needs have not been met. Previously, an evaluation initiated by Jiangsu Hengrui Medicine on the treatment of vulvovaginal candidiasis with Oteconazole